Revenue
2021
2022
2023
2024
2025
Kiniksa Pharmaceuticals International, plc (KNSA)
Price$79.05Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — | — | — | — |
| Gross profit | $599.9M | $362.3M | $236.9M | $197.3M | $29.4M | — | — | — | — |
| Gross margin | 88.54% | 85.61% | 87.64% | 89.60% | 76.39% | — | — | — | — |
| Research & development | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M | $112.0M | $135.0M | $86.6M | $56.4M |
| Operating expenses | $522.7M | $407.9M | $262.0M | $187.5M | $186.1M | $157.4M | $170.0M | $108.2M | $65.4M |
| Operating income | $77.2M | −$45.6M | −$25.2M | $9.8M | −$156.6M | −$157.4M | −$170.0M | −$108.2M | −$65.4M |
| Operating margin | 11.40% | −10.78% | −9.32% | 4.44% | −406.38% | — | — | — | — |
| EBITDA | $78.8M | −$43.9M | −$22.9M | $12.2M | −$154.3M | −$155.0M | −$167.9M | −$107.9M | −$65.4M |
| EBITDA margin | 11.63% | −10.38% | −8.46% | 5.53% | −400.27% | — | — | — | — |
| Net income | $59.0M | −$43.2M | $14.1M | $183.4M | −$157.9M | −$161.4M | −$161.9M | −$103.2M | −$64.9M |
| Net profit margin | 8.71% | −10.21% | 5.21% | 83.28% | −409.72% | — | — | — | — |
| Basic EPSper basic share | $0.80 | -$0.60 | $0.20 | $2.64 | -$2.30 | -$2.61 | -$2.99 | -$3.49 | -$35.85 |
| Diluted EPSper diluted share | $0.75 | -$0.60 | $0.20 | $2.60 | -$2.30 | -$2.61 | -$2.99 | -$3.49 | -$35.85 |
Owners
Reported shareholders
14.45%of listed shares
FMR LLC6.97M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.45%6.97M shares |
Rubric Capital Management LP | 8.29%4M shares |
BAKER BROS. ADVISORS LP | 5.88%2.83M shares |
BlackRock, Inc. | 5.68%2.74M shares |
TANG CAPITAL MANAGEMENT LLC | 4.68%2.26M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.96%1.91M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.82%1.36M shares |
Patel Sanj K | ≈2.36%1.14M shares |
MORGAN STANLEY | 2.10%1.01M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.98%957.51K shares |
Spruce Street Capital LP | 1.90%918.07K shares |
DIMENSIONAL FUND ADVISORS LP | 1.81%874.79K shares |
Invesco Ltd. | 1.60%772.81K shares |
Driehaus Capital Management LLC | 1.49%718.2K shares |
STATE STREET CORP | 1.46%704.19K shares |
ACADIAN ASSET MANAGEMENT LLC | 1.41%679.08K shares |
Point72 Asset Management, L.P. | 1.37%659.49K shares |
RICE HALL JAMES & ASSOCIATES, LLC | 1.30%624.93K shares |
Pictet Asset Management Holding SA | 1.26%608.65K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.25%604.18K shares |
Percentages use 48.24M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 1, 2026Form 4 · 10b5-1 | Paolini John F.CHIEF MEDICAL OFFICER | SellClass A Ordinary Share | 21.1K | $54.04 | $1.14M | 65.6K |
| May 1, 2026Form 4 · 10b5-1 | Paolini John F.CHIEF MEDICAL OFFICER | SellClass A Ordinary Share | 37.3K | $53.52 | $2.00M | 86.7K |
| May 1, 2026Form 4 · 10b5-1 | Patel Sanj KCHAIRMAN & CEO | SellClass A Ordinary Share | 48.6K | $54.02 | $2.62M | 0 |
| Apr 30, 2026Form 4 · 10b5-1 | Patel Sanj KCHAIRMAN & CEO | SellClass A Ordinary Share | 2.1K | $54.01 | $115.6K | 0 |
| Apr 29, 2026Form 4 · 10b5-1 | Patel Sanj KCHAIRMAN & CEO | SellClass A Ordinary Share | 22.5K | $54.01 | $1.22M | 0 |